方盛制药(603998.SH)：瑞卢戈利片药物临床试验获批准

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng"), has received approval from the National Medical Products Administration for the clinical trial of its generic drug, RuLuGuoLi tablets, for the treatment of prostate cancer [1] Group 1 - The clinical trial approval indicates a significant step forward in the development of RuLuGuoLi tablets [1] - The project is part of the company's strategy to expand its product offerings in the oncology sector [1]